Proactive Investors - Run By Investors For Investors

Midatech Pharma’s OpsiSporin showing ‘exceedingly good promise’ – CEO

Jim Phillips, chief executive of Midatech Pharma (LON:MTPH), says eye-disease drug OpsiSporin is on an accelerated programme in terms of investment priorities after it showed ‘exceedingly good promise’ with the company’s controlled release technology.  Philipps tells Proactive Investors that as revenue builds up the specialty pharma company will continue to spend ‘a lot of money’ on research and development to bring products to market.

In its full year results Midatech announced  proforma revenues for the combined business which were ‘well ahead of market expectations.’

 
Meet W Resources PLC, Avation PLC, Anglo Asian Mining PLC and Salt Lake Potash Ltd at our event, London , 28 February 2019. Register here »
View full MTPH profile View Profile

Midatech Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use